tbuckley/cabot-search huggingface dataset:
급성 독성 간손상의 임상적 양상
Authors: 김진배 ( Jin Bae Kim ), 손주현 ( Joo Hyun Sohn ), 이항락 ( Hang Lak Lee ), 김종표 ( Jong Pyo Kim ), 한동수 ( Dong Soo Han ), 함준수 ( Joon Soo Hahm ), 이동후 ( Dong Hoo Lee ), 기춘석 ( Chun Suhk Kee )
Journal: Clinical and Molecular Hepatology (2004)

목적: 연구자들은 최근 7년 간 급성 간염으로 진단된 환자에서 독성 간손상의 빈도와 임상 양상에 대해 알아보고자 하였다. 대상과 방법: 1996년 1월부터 2002년 12월까지 다른 원인에 의한 간염이 충분히 배제된 급성 독성 간손상으로 진단받은 68명을 대상으로 후향적으로 분석하였다. 진단기준은 CIOMS (Council for International Organizations of Medical Sciences)에서 제시한 진단기준에 따라 간세포형(hepatocellular), 담즙정체형(cholestatic), 혼합형(mixed) 간손상으로 분류하였고 기존의 만성 간질환에 독성 간손상이 병발된 경우, 알코올성 간염이 같이 의심되는 경우, 경미한 독성 간손상의 경우는 제외하였다. 결과: 1996년부터 2002년까지 연도별 급성 간염 중독성 간손상의 비율은 50-90로 매년 과반수 이상이었다. A형과 B형 간염은 유행 시기에 따라 매년 상호 간의 비율이 변동되었으며 급성 C형 간염은 매우 드물었다. 독성 간손상은 남녀 비는 여성이 70%로 많았고 평균 연령은 43세였다. 12.1%에서 독성 간손상의 과거력이 있었으며 3.1%에서 약물의 알레르기 병력이 있었다. 원인으로 상용 처방 약제에 의한 경우가 55%, 한약제나 녹즙 등 민간 요법에 의한 경우가 42%였다. 한약제와 상용 처방 약제를 같이 복용하여 구분할 수 없는 경우가 3%였다. 상용 처방 약제 중에는 항생제 계열이 60%로 가장 많았고 순수 소염제에 의한 경우는 19%였다. 그 밖에 항진균제, 항결핵제, 항전간제 순이었다. 증상은 황달이 56.5%로 가장 많았으며 전신 쇠약 50.8%, 피로감 49.2%, 오심 44.3% 순이었다. 황달을 호소한 환자의 54.3%에서 피부 소양감이 동반되었다. 초기 ALT, AST 평균 수치는 각각 847 IU/L, 664 IU/L였고 총 빌리루빈 평균치는 7.5 ㎎/dL였다. 초기 ALP 평균 수치는 196 IU/L였고 γ GTP 평균 수치는 269 IU/L였으며 프로트롬빈 평균 시간(%)은 86이었다. 호산구혈증(>5%)은 20%에서 동반되었다. 한약제군에서 상용 처방 약제군에 비해 약제 노출 기간이 의미 있게 길었으나(33.5일 대 12.7일, P<0.05), 두 군 간에 초기 ALT, AST, 총 빌리루빈, ALP, γ GTP 수치의 차이는 없었다. 모든 간기능 수치가 정상으로 회복되는데 소요된 평균 시간은 32일로 한약제군과 상용 처방 약제군 사이에 차이는 없었다. 임상 양상 중 간세포형이 45.2%, 담즙정체형이 22.5%, 혼합형이 32.3%였다. 결론: 최근 급성 간염의 원인으로 독성 간손상이 바이러스성 간염보다 흔하게 발생되고 있고 중등도 이상의 독성 간손상의 원인 약제로는 한약제군과 상용 처방 약제군이 서로 비슷한 비중을 차지하였다. 향후 전국적인 조사와 함께 약제 남용에 대한 경각과 홍보가 필요할 것으로 생각된다.
포스터발표 : 간경변 환자의 생존율 예측에 있어 Updated MELD와 updated MELD-Na이 기존 MELD 또는 Child-Pugh 점수에 비해 우수한가?
Authors: 김정한, 임형준, 안재홍, 김승영, 김동일, 윤재훈, 김진남, 정성우, 이홍식, 이상우, 최재현
Journal: Clinical and Molecular Hepatology (2009)
Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
Authors: D S Hoon, T Okamoto, H J Wang, R Elashoff, A J Nizze, L J Foshag, G Gammon, D L Morton
Journal: Journal of Clinical Oncology (1998)

PURPOSE An allogeneic polyvalent melanoma cell vaccine (PMCV) has been shown to be efficacious in improving overall survival of patients with malignant melanoma in a phase II clinical setting. The PMCV consists of three allogeneic melanoma cell lines. The objectives of the study were to determine (1) whether the survival of melanoma patients who received PMCV was related to the patient's human leukocyte antigen (HLA) class I phenotype matching the HLA class I phenotype of the PMCV, and (2) whether PMCV clinical efficacy was correlated to melanoma patients with a particular HLA phenotype(s). MATERIALS AND METHODS PMCV was given to 69 melanoma patients with American Joint Committee on Cancer (AJCC) stage I to IV disease status. The PMCV and patients lymphocytes were typed for HLA-A and -B. A correlation was made between the HLA expression of PMCV lines and the HLA of patients to their survival status. A second correlation was made between the HLA of patients and survival independent of the PMCV HLA phenotype. RESULTS Patients whose HLA phenotype (A3/11 and B7/44) matched the PMCV lines had a better overall survival (P &lt; .029). Analysis of HLA expression of patients independent of PMCV HLA to survival showed that HLA-A25 phenotype patients had a significantly better overall survival (P = .006). HLA-B35 patients had a poorer survival outcome (P = .019). CONCLUSION The studies indicate that overall survival following PMCV treatment in melanoma patients significantly correlates with their HLA phenotypes. These correlations may be related to the host immune response to the PMCV or due to differences in the clinical course of melanoma in patients with different HLA types.
Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study
Authors: M. Jhawer, H. L. Kindler, Z. Wainberg, J. Ford, P. Kunz, L. Tang, S. McCallum, H. Kallender, M. A. Shah
Journal: Journal of Clinical Oncology (2009)

4502 Background: GSK089 is an oral, small-molecule inhibitor of cMET and VEGFR2/KDR, and has potent antitumor activity in cMET-amplified cell lines and xenografts. cMET is reportedly amplified, overexpressed and/or activated in GC, making it an attractive therapeutic target. This phase II study examines the safety and efficacy of 2 dosing schedules of GSK089 as a single agent in patients (pts) with metastatic GC. Methods: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0–2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0–2 are sequentially enrolled in 2 cohorts: 1) Intermittent 5 days on/9 off - GSK089 240 mg/d on D1–5 repeated every 14 days, and 2) Daily - 80 mg/d. Primary study endpoint (response) is assessed every 8 weeks. cMET amplification by FISH (≥2 copies of cMET per copy of chromosome 7) is not an entry criterion, but is determined on archival tissue for all pts. Pre- and on-treatment tumor biopsies in select pts and plasma samples in all pts are analyzed for GSK089 effects on direct and downstream drug targets. GSK089 pharmacokinetics (PK) are also evaluated. Results: As of 12/19/08, enrollment to the 5 on/9 off cohort is complete with 41 evaluable pts, and 14 evaluable pts have enrolled on the daily cohort. cMET amplification was seen in 3/43 (7%) pts tested; all 3 were in 5 on/9 off cohort. Best response of stable disease (SD), was noted in 6/41 (15%) pts in the 5 on/9 off cohort (none were cMET-amplified), with 2 pts SD &gt;6 months, 1 ongoing; and in 3/14 (21%) pts in the daily cohort. Among all-enrolled pts (48 pts in 5 on/9 off, 16 pts in daily cohort), LFT abnormalities (9%), fatigue (5%), and venous thromboembolism (3%) were the most common GSK089 related grade 3- 4 adverse events (AE). Only 1 possibly related grade 5 AE, death due to unknown cause, was noted. Conclusions: GSK089 is well tolerated on both dosing schedules. cMET amplification in metastatic GC is rare. Single agent GSK089 demonstrates minimal antitumor activity in a cMET-unselected gastric population on the 5 on/9 off schedule. Enrollment on the daily dosing schedule continues, now with mandatory pre- and on-treatment biopsies to better define cMET pathway and target inhibition with GSK089. No significant financial relationships to disclose.
Medical Perspective on Nuclear Power
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angiogenesis success and pitfalls in diagnosis, therapy and cancer prevention
Authors: Adriana Albini
Journal: Clinical Cancer Research (2010)

Abstract In contrast to conventional chemotherapy, which targets the genetically mutated cancer cells, anti-vascular tumor therapy is primarily directed towards the newly formed blood vessel compartment, and is supposed to have the some advantages compared to conventional cytotoxic chemotherapy: (I) it is not restricted to a certain histologic tumor type, since all solid tumors depend on angiogenesis and the maintenance of functional microvasculature; (II) the tumor microvasculature is well accessible to systemic treatment; (III) it reaches the whole tumor mass, since every single tumor microvessel has to supply up to hundreds of critically dependent tumor cell layers; (IV) angiogenesis in adult organisms is only induced during the reproductive ovarian cycle or wound healing, thus an antagonism of angiogenesis should be a highly selective therapy; (V) the endothelial cell is genetically stable and therefore less prone to development of drug resistance. Recent evidences, however, show recurrence of tumor growth after an initial period of suppression during long-term therapy using antiangiogenic agents. Redundancy of alternative proangiogenetic factors in antiangiogenic monotherapies, upregulation of proangiogenic or anti-apoptotic factors, or heterogeneity of vascular dependency among tumor subpopulations are thought to be possible mechanisms for this phenomenon, as well as vascular remodeling. On the other hand, targeting angiogenic pathways can undermine elements and function of the cardiovascular system leading to potentially deadly side effects ranging from hypertension to heart failure. It is important to reconsider all the implications of antiangiogenic treatment to improve the therapeutic outcome and patients’ well being.
Prospective Molecular Evaluation of Small Cell Lung Cancer (Sclc) Utilizing the Comprehensive Mutation Analysis Program (Map) at Memorial Sloan Kettering Cancer Center (Mskcc)
Authors: L.M. Krug, M.C. Pietanza, A.M. Varghese, H. Won, L. Wang, N. Rekhtman, W.D. Travis, A. Litvak, P.K. Paik, G.J. Riely, M.F. Zakowski, M. Ladanyi, M.F. Berger, M. Kris, C.M. Rudin
Journal: Annals of Oncology (2014)
Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report
Authors: J.-C. Eymard, F. Joly, F. Priou, A. Zannetti, A. Ravaud, P. Kerbrat, M. Mousseau, B. Paule, F. Touze, E. Ecstein-Fraisse
Journal: Journal of Clinical Oncology (2004)

4603 Background: Single-agent docetaxel has proven efficacy in pts with HRPC, but the D and E combination is synergistic in vitro. This study evaluated PSA decline (PSA↓), safety, and quality of life (QoL) for DE vs D. Methods: Major eligibility criteria were: WHO PS \(\underline{{<}}\)2, appropriate renal, hepatic, and hematologic function, no prior chemotherapy, and withdrawal of antiandrogen therapy. Pts were randomized to Arm A (D 70 mg/m2IV over 1 hour d1 q3w + E 560 mg/d PO starting 1 day prior to D, for 5 consecutive days) or Arm B (D 75 mg/m2 IV over 1 hour d1 q3w) for a maximum of 6 cycles. Prophylactic warfarin (1mg/d PO) was given continuously in Arm A. Corticosteroid was given before and after D infusion in both arms. Results: Between 02/2001 and 10/2002, 92 pts were randomized (Arm A: 48, Arm B: 44) but 1 pt did not receive treatment. Median age was 68 years (range: 46–86), PS 0/1/2 (32/50/9 pts), median PSA was 115 ng/ml (range: 0.3–1585), and 40 pts (Arm A: 22, Arm B: 18) had measurable disease (MD). With a median number of 6 treatment cycles in both arms, cycle delays >7 days were more frequent in Arm A (15% pts) vs Arm B (11% pts); dose reduction was similar, 4.3% vs 4.5% pts, respectively. Median follow-up was 12.8 months. Main grade 3–4 hematologic toxicities among pts in Arms A vs B, respectively, were: neutropenia 25.5% vs 27.3%; anemia 10.6% vs 2.3%. Main grade 3−4 treatment toxicities (pts) were: thrombophlebitis (1) and allergic reaction (1) in Arm A; febrile neutropenia (1) per arm; fatal acute pulmonary edema (1) in Arm B. Response in Arm A vs B, respectively, was: PSA↓ >50%: 68% vs 29%; PSA↓ >75%: 36% vs 16%; median PSA response duration was 6 months in both arms. Of 40 pts with MD, PR was observed in 18.2% (Arm A) vs 16.7% (Arm B). Median time to progression in Arm A was 5.7 months (range: 4.7–5.8) vs 2.8 (2–6.9) in Arm B. There was no worsening in QoL using the FACT-P instrument and the pain score was stable throughout treatment in both arms. Conclusion: Docetaxel-based regimens are active in HRPC with predictable and manageable toxicity profiles. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Aventis
Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1- deamino-8-D-arginine vasopressin in humans
Authors: A Borchiellini, K Fijnvandraat, JW ten Cate, D Pajkrt, SJ van Deventer, G Pasterkamp, F Meijer-Huizinga, L Zwart-Huinink, J Voorberg, JA van Mourik
Journal: Blood (1996)
Contribution of increased afterload to right ventricular ejection fraction in pulmonary hypertension
Authors: Susana Hoette, Nicolas Creuze, Dominique Musset, David Montani, Florence Parent, Dermot O'Callaghan, Andrei Seferian, Olivier Sitbon, Gerald Simonneau, Marc Humbert, Denis Chemla
Journal: European Respiratory Journal (2011)

Background and aim: Right ventricular (RV) function is closely related to functional capacity and survival in pulmonary hypertension (PH). Our prospective cardiac magnetic resonance imaging (CMR) study attempted to quantify the contribution of increased RV afterload to the decreased right ventricular ejection fraction (RVEF) in PH patients.

Material and methods: 72 patients with precapillary PH (aged 59±15 years; 35F) underwent right heart catheterization and CMR on a 1.5 T scanner (Siemens) with electrocardiographic gating (delay ±48h). The main diagnoses were chronic thromboembolic PH (n=41) and pulmonary arterial hypertension (n=18). RVEF was calculated by using contiguous 6 mm RV short axis cines (balanced SSFP).

Results: Patients had increased mean pulmonary artery pressure (45±12 mmHg) and pulmonary vascular resistance (9±4 wu) and decreased RVEF (30±15%). The RVEF was more strongly related to RV end-systolic volume (RVESV = 78±36 mL/m2; r = -0.80) than to RV end-diastolic volume (RVEDV = 109±35 mL/m2; r = -0.53) (each P < 0.001). The combined influences of mean pulmonary artery pressure and pulmonary artery pulse pressure explained 27% of RVEF variability. The combined influences of pulmonary vascular resistance and pulmonary arterial compliance explained 37% of RVEF variability.

Conclusion: The classical indices quantifying RV afterload explained less than 40% of RVEF variability in PH, thus suggesting that other factors (e.g., decreased contractility, tricuspid insufficiency, cardiac remodeling) played a major role in right heart dysfunction.
Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin’s Lymphoma: Resolved Issues Versus Remaining Opportunity
Authors: Richard I. Fisher
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIAL Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.22.4411 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12431961 Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin’s Lymphoma: Resolved Issues Versus Remaining Opportunity Richard I. FisherxRichard I. FisherSearch for articles by this author Show More James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY https://doi.org/10.1200/JCO.2002.20.22.4411 Full Text PDF Figures and Tables "Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin’s Lymphoma: Resolved Issues Versus Remaining Opportunity." Journal of Clinical Oncology, 20(22), pp. 4411–4412© 2002 by American Society of Clinical Oncology
Factors predicting silent brain metastases in patients with non-small-cell lung cancer
Authors: I. Na, T. Lee, D. Choe, H. Kang, J. Koh, J. Park, H. Baek, C. Kim, B. Ryoo, J. Lee, S. Yang
Journal: Journal of Clinical Oncology (2008)

19131 Background: This study launched to identify predictive factors and discriminate subgroups according to risk of brain metastases in non-small-cell lung cancer (NSCLC) patients who have not neurological symptoms. Methods: We performed retrospective review of 446 NSCLC patients who underwent computed tomography (CT), magnetic resonance imaging (MRI) and bone scan at initial staging work-up between April 2003 and April 2007. Brain metastases were determined by MRI. Patients were stratified into groups according to number of risk factors identified in multivariate analysis. Multilevel likelihood ratio (LR) was calculated for each group. Results: Thirty-three patients had brain metastasis. Histopathology of adenocarcinoma, nodal stage ≥ 2 on CT and bone metastasis were predictive factors of brain metastasis in multivariate analysis. Patients were divided into four groups sequentially according to number (0 to 3) of predictive factors of brain metastasis. The proportion of patients with brain metastasis in four groups was 3%, 5%, 18%, and 38%, respectively and its difference was significant (P < 0.001). LRs of four groups ranged from 0.2 to 7.7 (0.3, 0.6, 2.8 and 7.7, respectively). Within 33 patients with brain metastasis, there was a significant different proportion of single brain metastasis according to number of predictors (P < 0.001). Conclusions: These results suggest that the predictive model using number of risk factors may be useful to identify silent brain metastasis in NSCLC patients. No significant financial relationships to disclose.
Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer
Authors: L. Chen, N. J. Vogelzang, G. Blumenschein, F. Robert, J. M. Pluda, S. R. Frankel, S. Sharma
Journal: Journal of Clinical Oncology (2007)

18088 Background: Pem and CDDP are active agents in many tumor types, and the combination is approved as first line therapy in malignant pleural mesothelioma (meso). Vorinostat (V), an orally active histone deacetylase inhibitor, was shown to induce PR in 2 meso patients (pts) (Krug 2006, Kelly 2005). A Phase I trial was undertaken to determine the safety and maximum tolerated dose (MTD) of Pem+CDDP+V. Methods: Pts with advanced solid malignancies, adequate organ function, ECOG PS = 2, = 1 prior chemotherapy, &gt;18 yrs of age, and at least 6 months from prior treatment with Pem+CDDP were eligible. Patients were treated on 21 day cycles. V was started 2 days before standard doses of CDDP (75 mg/m 2 ) and Pem (500 mg/m 2 ) and was given on 4 schedules: dose levels were: I-200 mg BID for 14/21 d, II- 300 mg BID for 3/7 d wk1, 2 wk rest, III-300 mg QD for 7/21 d, and IV- 400 mg QD for 7/21 d. Results: Twenty-two pts were treated: median age was 60 (range 31–81); 13M: 9F. Tumor types were NSCLC 8, meso 5, bladder 3, colorectal 2, other 4. Nineteen of 22 patients were evaluable for investigator determined response: 1 CR (5.3%), 1 PR (5.3%), 11 SD (57.9%), 6 PD (31.6%). Conclusions: Dehydration and fatigue were common DLTs on different schedules of Pem+CDDP+V. V 300 mg x 7 days was tolerable in this combination. Hints of clinical activity were observed in bladder cancer and sarcoma patients, and stable disease was seen in three mesothelioma patients. Alternative dose schedules of Pem + V are under investigation. [Table: see text] No significant financial relationships to disclose.
Effect of wheat grass juice in supportive care of terminally ill cancer patients— A tertiary cancer centre experience from India
Authors: S. Dey, R. Sarkar, P. Ghosh, R. Khatun, K. Ghorai, R. Choudhury, R. Ahmed, P. Gupta, S. Mukhopadhyay, A. Mukhopadhyay
Journal: Journal of Clinical Oncology (2006)

8634 Background: The solid content of juice made from wheat grass is 70% chlorophyll. Chlorophyll is often referred to as “The blood of plant life” and has almost the same chemical structure as haemoglobin. Chlorophyll cleanses the blood by improving the supply of oxygen to the circulatory system. Wheat grass is also a complete protein with about 30 enzymes, vitamins &amp; minerals. Wheat grass juice has been proven over many years to benefit people in numerous ways, building the blood, restoring balance in the body, removing toxic metals from the cells, nourishing the liver &amp; kidneys and restoring vitality. The aim of our study was to see the effect of wheat grass juice in terminally ill cancer patients to improve the quality of life. Methods: During period from January 2003 to December 2005 we selected 400 solid organ cancer patients in our palliative care unit of Netaji Subhash Chandra Bose Cancer Research Institute to see the effect of wheat grass on improvement of haemoglobin level, serum protein &amp; performance status on terminally ill cancer patients. The age range of the patients was 22 year to 87 year (median age 42 years). The different types of cancers were Lung (25%), Breast (20%), Oesophagaus (11%), Colon (9%), Ovary (8%), Hepatocellular carcinoma (6%), Stomach (6%) and others (15%) respectively. We cultivated wheat grass in our campus. When the grasses were 5 days old we took the fresh leaves including roots and made fresh juice out of that and had given 30ml of juice to all our 400 cancer patients for continuous 6 months. Result: The mean levels of haemoglobin, Serum total protein, albumin and performance status were 8gm%, 5.4gm%, 2.2gm% and 50%. Fifty patients required transfusion support &amp; those patients were excluded from the study. Other 348 patients are evaluated 6 months after giving wheat grass juice. The mean values for haemoglobin, total protein &amp; albumin were improved significantly (pvalue &lt; .005) and were observed mean of 9.6gm%, 7.4gm% and 3.1gm%. White blood cell &amp; platelet count were same in both the cases. The performance status was improved from 50% to 70% (Karnofsky) after wheat grass treatment. Conclusion: We concluded that wheat grass juice is an effective alternative of blood transfusion. Its use in terminally ill cancer patients should be encouraged. No significant financial relationships to disclose.
Predictors of Response to Preoperative Chemoradiotherapy (Crt) for Rectal Adenocarcinoma: Biopsy Specimens Obtained 1 Week After Starting Treatment are a Reliable Prognostic Factor
Authors: T. Suzuki, S. Sadahiro, A. Tanaka, K. Okada, G. Saito
Journal: Annals of Oncology (2014)
Novel Proteasome Inhibitors Induce Mitochondrial Destabilization and Activate Caspase Mediated Apoptosis In Preclinical Models Of Pediatric B-Cell Cancers
Authors: Aneel Paulus, Kasyapa S. Chitta, Eric Sandler, Sharoon Akhtar, Maja Kuranz, Han Tun, Vivek Roy, James M. Foran, Kena Miller, Candido E. Rivera, Asher Chanan-Khan
Journal: Blood (2013)
Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma
Authors: Florence Magrangeas, Philippe Moreau, Loic Campion, Herve Avet-Loiseau, Catherine Guérin, Wilfried Gouraud, Gérald Marit, Michel Attal, Denis Caillot, Thierry Facon, Cyrille Hulin, Lotfi Benboubker, Brigitte Pegourie, Stephane Minvielle
Journal: Blood (2013)